Clinical Trial Update: Samsca Post Marketing Surveillance Study

View source ↗

Summary

Post-marketing surveillance trial update for Samsca (tolvaptan) with completed status and posted results as of 2020-03-06.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Euvolemic Hyponatremia
• Hypervolemic Hyponatremia

Drugs mentioned

• Samsca (tolvaptan)

Snippet

Sponsor: Korea Otsuka Pharmaceutical Co., Ltd. | Conditions: Hypervolemic and Euvolemic Hyponatremia | Status: COMPLETED | Results posted: 2020-03-06